48 results on '"Raza, Azra"'
Search Results
2. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib inRAS-mutant relapsed or refractory myeloid malignancies
3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
4. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure
5. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
6. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
7. MicroRNAs in myeloproliferative neoplasms
8. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
9. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome
10. A Pluralistic Approach to the Study of Myelodysplastic Syndromes: Evolving Pathology of the Seed via the Soil
11. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes
12. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes
13. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
14. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T‐cell expansion
15. Myelodysplastic syndromes
16. Decitabine improves patient outcomes in myelodysplastic syndromes
17. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes
18. Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients
19. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
20. Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1
21. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes
22. INCREASED MACROPHAGES, HIGH SERUM M‐CSF AND LOW SERUM CHOLESTEROL IN MYELODYSPLASIA AND KAWASAKI DISEASE
23. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
24. Evidence for involvement of tumor necrosis factor‐α in apoptotic death of bone marrow cells in myelodysplastic syndromes
25. Evidence for involvement of tumor necrosis factor-? in apoptotic death of bone marrow cells in myelodysplastic syndromes
26. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis
27. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study
28. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia
29. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia
30. The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study
31. Contribution ofin vivo proliferation/differentiation studies toward the development of a combined functional and morphologic system of classification of neoplastic diseases
32. The role of emerging technologies in the diagnosis and staging of neoplastic diseases
33. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure
34. Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia
35. Effects of rGM-CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA
36. Detection of monosomy 7 in interphase cells of patients with myeloid disorders
37. Improved rapid autoradiography with elimination of background
38. Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia
39. Immunofluorescent staining method for use with monoclonal antibodies
40. Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986
41. Utility and sensitivity of anti BrdU antibodies in assessing S-phase cells compared to autoradiography
42. Analysis of cell cycle characteristics and course of the disease in ANLL
43. Differences between labeling index and DNA histograms in assessing s-phase cells from a homogenous group of chronic phase CML patients
44. Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia
45. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
46. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
47. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
48. Myelodysplastic syndromes: incidence and survival in the United States.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.